Yesterday, I brought you the nice. Today, it’s the naughty: the nominees for the worst biopharma CEO of 2017.

Even in a good year for biopharma, there’s always a crop of CEOs, through their actions or words, who manage to screw up badly enough to make the rest of us cringe. Or get angry. I always have fun compiling this list of bungling biopharma CEOs. And here they are. You’ll get a chance to vote at the bottom of this post.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

CytRx is notable as one of the very few penny stocks that has been used more than once as a pump-and-dump vehicle by Howard Appel and Mark Tompkins, both stock fraud recidivists. Most stocks they exploit are left for ruin after one round. But go through past years of penny-stock promoters’ newsletters, and you’ll find that CytRx gets the fraud treatment a few times over the years. This company has never had any actual concrete drug development plans.

This is the total embodiment of greed and the absolute greed of our “health care system”.
Such is the concern of our Congress. Personal gain; certainly not the welfare of our people.
We have become a society of greed with no concern of the overall good.
Sad, but TRUE